Results and outlook shock Sanofi investors as shares slide 19%

27 October 2023
sanofi_large

In a third-quarter2023 financial results season when most pharma companies have pleased shareholders with better-than-expected figures, the reaction to Sanofi’s presentation on Friday has provided a stark contrast.

Shares in the French drugmaker were down by around 19% as the trading day neared its end in Paris, as markets mulled over results that had missed estimates, a lower profit outlook and a spinout of Sanofi’s consumer care unit.

Sales for the quarter were more than 4% lower than in the same period a year ago, at 11.96 billion euros ($12.66 billion), while business operating income dropped by 10% to 4.03 billion euros, slightly below consensus estimates published on its website.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical